As part of their investigations into the safety of these treatments, health experts in charge have warned about probable negative effects from weight reduction injections in ten cases where people d!ed.
The UK Medicines and Healthcare Products Regulatory Agency (FHRA) is looking into the safety of weight reduction injections after a number of patients were diagnosed with pancreatitis.
Officials are looking into whether a genetic disease that affects persons with the ailment makes them more likely to take dr*gs like Mounjaro Wegovy or Ozempic.
Using dr*gs to assist people lose weight has been a popular topic of conversation in the previous few years.
Some famous people and influencers have been talking about GLP-1 injections to assist people lose weight, even though the real purpose is to help patients with type 2 diabetes control their blood sugar.
Health specialists at the MHRA think that there may be a link between GLP-1 dr*gs and chronic inflammation of the pancreas.
There have been reports of a number of negative effects, and some people think that these dr*gs may have caused some fatalities.
But there is no clear proof that the medicine is directly responsible for de@ths.
The MHRA said that it had witnessed more than 560 cases of persons getting pancreatitis after getting GLP-1 injections. The UK’s medical authority wants people who go to the hospital for pancreatitis treatment to let the authorities know about any bad reactions through a Yellow Card initiative. The illness usually causes severe stomach pain that can move to the back and not go away. If you feel this way, you should consult a doctor right away.
MailOnline says that if a patient signs up by sending in the Yellow Card report, the MHRA will phone them to ask if they want to be part of the current Biobank project, which is being done alongside Genomics England.
Patients should give an oral sample to see if their genetics make them more likely to get acute pancreatitis when taking GLP-1. Then, before giving these dr*gs, doctors can do a genetic test.
Dr. Alison Cave, the MHRA’s top safety officer, told the publication that genetic testing might avert almost a third of the unwanted effects of dr*gs.
The adverse effects of these treatments are projected to cost patients and the NHS more than £2.2 billion a year for hospital stays.
There have been 181 occurrences of both chronic and acute pancreatitis reported to the MHRA after getting a known shot.
There are also 113 occurrences of chronic and acute pancreatitis, which is caused by an active ingredient in two different GLP-1 injections.
Information from the Yellow Card Biobank will help us figure out who is most likely to have bad reactions. This will let us give the best therapy to patients all over the UK based on their genetic makeup.
We want to aid people who are in need, so we’re asking anyone who has been hospitalized with acute pancreatitis and is taking GLP-1 medicine to let us know through the Yellow Card scheme.
Nausea, constipation, and diarrhea are among the possible side effects of these shots.
A representative from Novo Nordisk told LADbible, “The safety of our patients is the most important thing to us.” Like with all medicines, some people may have bad reactions, and these can be different for each person. The Abstract of characteristics of the product talks about the pros and cons of GLP1 dr*gs.
We recommend that patients only take these dr*gs when they are approved for use and under the supervision of a skilled healthcare professional, who can also tell them about any possible negative effects.
We are still gathering information about the safety of the GLP-1 treatments we sell, and we work closely with the authorities to make sure that patients are safe. The benefit-risk profile of our GLP-1 dr*gs is still good, and we welcome any new study that will help us learn more about the best ways to treat people with chronic conditions.
A Lilly spokeswoman told LADbible that Lilly’s top priority is the safety of its patients. We care about the safety of our patients. We carefully look at, keep an eye on, and give safety information on all of our medicines. The MHRA’s Yellow Card scheme says that all bad events must be recorded, although they could also be caused by other things somewhere else, including by having a medical condition filled in the blank.
The Mounjaro (tripeptide) Patient Information Leaflet tells patients that an inflamed pancreas (acute pancreatitis) is a rare adverse effect that can happen to as many as 1 out of 100 people. It also says that anyone who have had pancreatitis should talk to their doctor or another medical practitioner before using Mounjaro.
We suggest that patients talk to their doctor or another healthcare practitioner about any bad reactions they may be having and to be sure they are getting real Lilly dr*gs.